
Opinion|Videos|January 25, 2025
Differentiating Treatment Options: Epcoritamab + R2 vs Tafasitamab-Lenalidomide-Rituximab in R/R FL
Panelists discuss how they anticipate differentiating candidates for epcoritamab + lenalidomide and rituximab (R2) vs those better suited for tafasitamab-lenalidomide-rituximab, considering the factors that most influence their decisions, and share their impressions of the EPCORE NHL-2 trial, including potential treatment sequencing implications between the 2 regimens.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you anticipate differentiating candidates for epcoritamab[JS1] + R2 and those who might be better suited for a tafasitamab-lenalidomide-rituximab? What factors most influence your decision?
- Feel free to share your thoughts on any differences and/or similarities in your impressions of the EPCORE NHL-2 trial, and potential treatment sequencing implications between tafasitamab-lenalidomide-rituximab vs epcoritamab + R2.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5





































